Targeting of the MYCN protein with small molecule c-MYC inhibitors

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Müller, Inga ^a   Larsson, Karin ^a   Frenzel, Anna ^a   Oliynyk, Ganna ^a   Zirath, Hanna ^a   Prochownik, Edward V ^b   Westwood, Nicholas J ^c   Henriksson, Marie Arsenian ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c Fife   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C MYC INHIBITOR 10058 F4; C MYC INHIBITOR 10058 F47RH; C MYC INHIBITOR 10074 G5; C MYC INHIBITOR 474; C MYC INHIBITOR 764; C MYC INHIBITOR C M Z 232; MYC PROTEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; 10074-G5; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; MOLECULAR LIBRARY; MYC ASSOCIATED FACTOR X; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; OXADIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIPID STORAGE; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NEUROBLASTOMA; NEUROBLASTOMA CELL; ONCOGENE MYC; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; LIPID METABOLISM; METABOLISM; MOLECULAR GENETICS; MOLECULAR LIBRARY; PATHOLOGY; PHARMACOLOGY; PROTEIN DEGRADATION; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; APOPTOSIS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LIPID METABOLISM; MOLECULAR SEQUENCE DATA; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; OXADIAZOLES; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-MYC; SMALL MOLECULE LIBRARIES;

EID: 84901399341     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097285     Document Type: Article

References (54)

1. Vita M, Henriksson M (2006) The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16: 318-330. (Pubitemid 44311040)
2. Meyer N, Penn LZ (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990.
3. Luscher B, Larsson LG (1999) The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation. Oncogene 18: 2955-2966. (Pubitemid 29276536)
4. Malynn BA, de Alboran IM, O'Hagan RC, Bronson R, Davidson L, et al.(2000) N-myc can functionally replace c-myc in murine development, cellular growth and differentiation. Genes and Dev 14: 1390-1399. (Pubitemid 30397082)
5. Downs KM, Martin GR, Bishop JM (1989) Contrasting patterns of myc and N-myc expression during gastrulation of the mouse embryo. Genes Dev 3: 860-869.
6. Zimmerman KA, Yancopoulos GD, Collum RG, Smith RK, Kohl NE, et al. (1986) Differential expression of myc family genes during murine development. Nature 319: 780-783. (Pubitemid 16145034)
7. Hirvonen H, Makela TP, Sandberg M, Kalimo H, Vuorio E, et al. (1990) Expression of the myc proto-oncogenes in developing human fetal brain. Oncogene 5: 1787-1797. (Pubitemid 120034705)
8. Mugrauer G, Alt FW, Ekblom P (1988) N-myc proto-oncogene expression during organogenesis in the developing mouse as revealed by in situ hybridization. J Cell Biol 107: 1325-1335.
9. Stanton BR, Parada LF (1992) The N-myc proto-oncogene: developmental expression and in vivo site-directed mutagenesis. Brain Pathol 2: 71-83.
10. Albihn A, Johnsen JI, Henriksson MA (2010) MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 107: 163-224.
11. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
12. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369: 2106-2120. (Pubitemid 46935947)
13. Larsson LG, Henriksson MA (2010) The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res 316: 1429-1437.
14. Prochownik EV, Vogt PK (2010) Therapeutic Targeting of Myc. Genes Cancer 1: 650-659.
15. Felsher DW (2010) MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer 1: 597-604.
16. Felsher DW, Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4: 199-207. (Pubitemid 29456888)
17. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, et al. (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297: 102-104. (Pubitemid 34743102)
18. Pelengaris S, Khan M, Evan GI (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321-334. (Pubitemid 34606875)
19. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G (1999) Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3: 565-577. (Pubitemid 29268440)
20. Shachaf CM, Felsher DW (2005) Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res 65: 4471-4474. (Pubitemid 40740778)
21. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, et al. (2004) MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112-1117. (Pubitemid 39472236)
22. Soucek L, Evan GI (2010) The ups and downs of Myc biology. Curr Opin Genet Dev 20: 91-95.
23. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, et al. (2008) Modelling Myc inhibition as a cancer therapy. Nature 455: 679-683.
24. Dang CV (2012) MYC on the path to cancer. Cell 149: 22-35.
25. Loke SL, Stein C, Zhang X, Avigan M, Cohen J, et al. (1988) Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis. Curr Top Microbiol Immunol 141: 282-289.
26. Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH (2002) Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci U S A 99: 11593-11598. (Pubitemid 34994444)
27. Berg T, Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, et al. (2002) Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A 99: 3830-3835. (Pubitemid 34252191)
28. Yin X, Giap C, Lazo JS, Prochownik EV (2003) Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22: 6151-6159. (Pubitemid 37281644)
29. Follis AV, Hammoudeh DI, Daab AT, Metallo SJ (2009) Small-molecule perturbation of competing interactions between c-Myc and Max. Bioorg Med Chem Lett 19: 807-810.
30. Follis AV, Hammoudeh DI, Wang H, Prochownik EV, Metallo SJ (2008) Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol 15: 1149-1155.
31. Harvey SR, Porrini M, Stachl C, MacMillan D, Zinzalla G, et al. (2012) Small-molecule inhibition of c-MYC:MAX leucine zipper formation is revealed by ion mobility mass spectrometry. J Am Chem Soc 134: 19384-19392.
32. Michel J, Cuchillo R (2012) The impact of small molecule binding on the energy landscape of the intrinsically disordered protein C-myc. PLoS One 7: e41070.
33. Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE (2006) A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 34: 1480-1489. (Pubitemid 44548118)
34. Lin CP, Liu JD, Chow JM, Liu CR, Liu HE (2007) Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs 18: 161-170.
35. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, et al. (2010) c-Myc Regulates Transcriptional Pause Release. Cell 141: 432-445.
36. Guo J, Parise RA, Joseph E, Egorin MJ, Lazo JS, et al. (2009) Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol 63: 615-625.
37. Clausen DM, Guo J, Parise RA, Beumer JH, Egorin MJ, et al. (2010) In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther 335: 715-727.
38. Hammoudeh DI, Follis AV, Prochownik EV, Metallo SJ (2009) Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc 131: 7390-7401.
39. Wang H, Hammoudeh DI, Follis AV, Reese BE, Lazo JS, et al. (2007) Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 6: 2399-2408. (Pubitemid 47480405)
40. Zirath H, Frenzel A, Oliynyk G, Segerstrom L, Westermark UK, et al. (2013) MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci U S A 110: 10258-10263.
41. Dyson HJ, Wright PE (2005) Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 6: 197-208. (Pubitemid 40314921)
42. Andrade MA, Chacon P, Merelo JJ, Moran F (1993) Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. Protein Eng 6: 383-390. (Pubitemid 23197398)
43. Sreerama N, Venyaminov SY, Woody RW (2000) Estimation of protein secondary structure from circular dichroism spectra: inclusion of denatured proteins with native proteins in the analysis. Anal Biochem 287: 243-251. (Pubitemid 32006233)
44. Sreerama N, Woody RW (1994) Protein secondary structure from circular dichroism spectroscopy. Combining variable selection principle and cluster analysis with neural network, ridge regression and self-consistent methods. J Mol Biol 242: 497-507.
45. van Stokkum IH, Spoelder HJ, Bloemendal M, van Grondelle R, Groen FC (1990) Estimation of protein secondary structure and error analysis from circular dichroism spectra. Anal Biochem 191: 110-118.
46. Whitmore L, Wallace BA (2004) DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res 32: W668-673. (Pubitemid 38997420)
47. Whitmore L, Wallace BA (2008) Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases. Biopolymers 89: 392-400.
48. Fieber W, Schneider ML, Matt T, Kräutler B, Konrat R, et al. (2001) Structure, Function, and Dynamics of the Dimerization and DNA-binding Domain of Oncogenic Transcription Factor v-Myc. J Mol Biol 307: 1395-1410. (Pubitemid 33027648)
49. Edsjo A, Holmquist L, Pahlman S (2007) Neuroblastoma as an experimental model for neuronal differentiation and hypoxia-induced tumor cell dedifferentiation. Semin Cancer Biol 17: 248-256. (Pubitemid 46413077)
50. Knoepfler PS, Cheng PF, Eisenman RN (2002) N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 16: 2699-2712.
51. Loven JZ, Zinin N, Wahlström T, Müller I, Brodin P, et al. (2010) MYCN-regulated microRNAs repress estrogen receptor-a (ESR 1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci U S A 107: 1553-1558.
52. Yap JL, Wang H, Hu A, Chauhan J, Jung KY, et al. (2013) Pharmacophore identification of c-Myc inhibitor 10074-G5. Bioorg Med Chem Lett 23: 370-374.
53. Wang HC, Hu J, Pendleton A, Yap K, Sabato JL, et al. (2013) Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5. Oncotarget 4: 936-947.
54. Albihn A, Loven J, Ohlsson J, Osorio LM, Henriksson M (2006) c-Myc-dependent etoposide-induced apoptosis involves activation of Bax and caspases, and PKCdelta signaling. J Cell Biochem 98: 1597-1614. (Pubitemid 44141863)